advertisement

Oculus

11.16 Vehicles, delivery systems, pharmacokinetics, formulation (65)

Showing records 1 to 25

Display all abstracts in classification 11.16 Vehicles, delivery systems, pharmacokinetics, formulation

Search within classification 11.16 Vehicles, delivery systems, pharmacokinetics, formulation
77935 Controlled-release nanotherapeutics: State of translation
Tan YF
Journal of Controlled Release 2018; 284: 39-48
78105 Treatment merits of Latanoprost/Thymoquinone - Encapsulated liposome for glaucomatus rabbits
Fahmy HM
International Journal of Pharmaceutics 2018; 548: 597-608
78109 The RELIEF study: Tolerability and efficacy of preservative-free latanoprost in the treatment of glaucoma or ocular hypertension
Misiuk-Hojlo M
European Journal of Ophthalmology 2018; 0: 1120672118785280
78129 Amino-Functionalized Mesoporous Silica Particles for Ocular Delivery of Brimonidine
Kim SN
Molecular pharmaceutics 2018; 15: 3143-3152
77935 Controlled-release nanotherapeutics: State of translation
Tan YF
Journal of Controlled Release 2018; 284: 39-48
78256 Old and New Drug Classes Expanding To Include Glaucoma Treatments
Kish T
P and T 2018; 43: 489-502
78135 Montmorillonite/chitosan nanoparticles as a novel controlled-release topical ophthalmic delivery system for the treatment of glaucoma
Li J
International Journal of Nanomedicine 2018; 13: 3975-3987
78172 Topical Curcumin Nanocarriers are Neuroprotective in Eye Disease
Davis BM
Scientific reports 2018; 8: 11066
78156 Reduction in Ocular Hypotensive Eyedrops by Ab Interno Trabeculotomy Improves Not Only Ocular Surface Condition But Also Quality of Vision
Kashiwagi K
Journal of Ophthalmology 2018; 2018: 8165476
78063 Preservatives in glaucoma medication
Steven DW
British Journal of Ophthalmology 2018; 102: 1497-1503
78172 Topical Curcumin Nanocarriers are Neuroprotective in Eye Disease
Pahlitzsch M
Scientific reports 2018; 8: 11066
78063 Preservatives in glaucoma medication
Alaghband P
British Journal of Ophthalmology 2018; 102: 1497-1503
78105 Treatment merits of Latanoprost/Thymoquinone - Encapsulated liposome for glaucomatus rabbits
Saad EAES
International Journal of Pharmaceutics 2018; 548: 597-608
78135 Montmorillonite/chitosan nanoparticles as a novel controlled-release topical ophthalmic delivery system for the treatment of glaucoma
Tian S
International Journal of Nanomedicine 2018; 13: 3975-3987
78156 Reduction in Ocular Hypotensive Eyedrops by Ab Interno Trabeculotomy Improves Not Only Ocular Surface Condition But Also Quality of Vision
Matsubara M
Journal of Ophthalmology 2018; 2018: 8165476
77935 Controlled-release nanotherapeutics: State of translation
Lao LL
Journal of Controlled Release 2018; 284: 39-48
78109 The RELIEF study: Tolerability and efficacy of preservative-free latanoprost in the treatment of glaucoma or ocular hypertension
Pomorska M
European Journal of Ophthalmology 2018; 0: 1120672118785280
78129 Amino-Functionalized Mesoporous Silica Particles for Ocular Delivery of Brimonidine
Ko SA
Molecular pharmaceutics 2018; 15: 3143-3152
78172 Topical Curcumin Nanocarriers are Neuroprotective in Eye Disease
Guo L
Scientific reports 2018; 8: 11066
78109 The RELIEF study: Tolerability and efficacy of preservative-free latanoprost in the treatment of glaucoma or ocular hypertension
Mulak M
European Journal of Ophthalmology 2018; 0: 1120672118785280
78129 Amino-Functionalized Mesoporous Silica Particles for Ocular Delivery of Brimonidine
Park CG
Molecular pharmaceutics 2018; 15: 3143-3152
78063 Preservatives in glaucoma medication
Lim KS
British Journal of Ophthalmology 2018; 102: 1497-1503
78105 Treatment merits of Latanoprost/Thymoquinone - Encapsulated liposome for glaucomatus rabbits
Sabra NM
International Journal of Pharmaceutics 2018; 548: 597-608
78135 Montmorillonite/chitosan nanoparticles as a novel controlled-release topical ophthalmic delivery system for the treatment of glaucoma
Tao Q
International Journal of Nanomedicine 2018; 13: 3975-3987
77935 Controlled-release nanotherapeutics: State of translation
Xiong GM
Journal of Controlled Release 2018; 284: 39-48

Issue 19-4

Select Issue


advertisement

HaagStreit